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Peptides derived from animal venoms provide important research tools for biochemical
and pharmacological characterization of receptors, ion channels, and transporters.
Some venom peptides have been developed into drugs (such as the synthetic
ω-conotoxin MVIIA, ziconotide) and several are currently undergoing clinical trials for
various clinical indications. Challenges in the development of peptides include their
usually limited supply from natural sources, cost-intensive chemical synthesis, and
potentially complicated stereoselective disulfide-bond formation in the case of disulfide-
rich peptides. In particular, if extended structure–function analysis is performed or
incorporation of stable isotopes for NMR studies is required, the comparatively low
yields and high costs of synthesized peptides might constitute a limiting factor. Here we
investigated the expression of the 4/7 α-conotoxin TxIA, a potent blocker at α3β2 and
α7 nicotinic acetylcholine receptors (nAChRs), and three analogs in the form of maltose
binding protein fusion proteins in Escherichia coli. Upon purification via nickel affinity
chromatography and release of the toxins by protease cleavage, HPLC analysis revealed
one major peak with the correct mass for all peptides. The final yield was 1–2 mg of
recombinant peptide per liter of bacterial culture. Two-electrode voltage clamp analysis
on oocyte-expressed nAChR subtypes demonstrated the functionality of these peptides
but also revealed a 30 to 100-fold potency decrease of expressed TxIA compared to
chemically synthesized TxIA. NMR spectroscopy analysis of TxIA and two of its analogs
confirmed that the decreased activity was due to an alternative disulfide linkage rather
than the missing C-terminal amidation, a post-translational modification that is common
in α-conotoxins. All peptides preferentially formed in the ribbon conformation rather
than the native globular conformation. Interestingly, in the case of the α7 nAChR, but
not the α3β2 subtype, the loss of potency could be rescued by an R5D substitution.
In conclusion, we demonstrate efficient expression of functional but alternatively folded
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ribbon TxIA variants in E. coli and provide the first structure–function analysis for a ribbon
4/7-α-conotoxin at α7 and α3β2 nAChRs. Computational analysis based on these data
provide evidence for a ribbon α-conotoxin binding mode that might be exploited to
design ligands with optimized selectivity.
Keywords: E. coli, recombinant expression, 4/7 α-conotoxin, ribbon isomer, molecular modeling, NMR
spectroscopy
INTRODUCTION
Nicotinic acetylcholine receptors (nAChRs) are members of the
Cys-loop superfamily of pentameric ligand-gated ion channels.
Whereas the muscle-type receptors consist of four different
subunits (α1,β1,γ/ε,δ), the assembly and stoichiometry of the
11 cloned neuronal subunits (α2–α7, α9, α10, and β2–β4) into
nAChR subtypes is considerably more diverse and not well-
defined. These neuronal nAChRs represent important drug
targets such as for the treatment of pain, Alzheimer’s disease, and
nicotine addiction (Dineley et al., 2015; Lombardo and Maskos,
2015; Mohamed et al., 2015; Giribaldi and Dutertre, 2018; Hone
and McIntosh, 2018). Deciphering their specific compositions
and location in nervous system tissues as well as their respective
physiological roles requires highly selective ligands.
Venoms from animals contain complex mixtures of small
proteins and peptides that are often structurally constrained by
disulfide bridges. Some of these peptides show high potency
and specificity for certain ion channel subtypes. Cone snails are
predatory marine animals that have evolved numerous peptide
families that target various ligand- and voltage-gated ion channels
(Akondi et al., 2014). The best-studied conotoxin family from
a pharmacological perspective is the α-conotoxins, members of
which are competitive antagonists of nAChRs (Dutertre et al.,
2017). Some of these peptides have analgesic activity in vivo and
thus are important lead structures for drug development (Akondi
et al., 2014; Mohammadi and Christie, 2015).
The majority of α-conotoxins are composed of 12–19 amino
acid residues including four cysteine residues that form two
disulfide bonds. The cysteines are arranged in a CC–C–C pattern
that defines the conotoxin Cysteine Framework I (Kaas et al.,
2010). This framework is characterized by vicinal Cys1 and Cys2
residues and two loops formed by Cys1–Cys3 and Cys2–Cys4
disulfide bridges (referred to as the “globular” conformation).
Based on the number of amino acid residues within the two loops,
the currently characterized α-conotoxins are further classified
into 3/4, 4/4, 3/5, 4/6, and 4/7 α-conotoxin subfamilies. These
subfamilies show some common specificity for certain nAChR
subtypes, with for example, the 3/5 α-conotoxins targeting
the muscle-type nAChR and most identified 4/7 α-conotoxins
preferentially targeting α7 and/or α3β2∗ neuronal nAChRs
(∗ indicates the potential presence of further subunits) (Dutertre
et al., 2017). Understanding the structure-activity relationships
of conotoxins might aid in the development of optimized
peptides with tailored selectivity. Usually, such studies employ
chemical synthesis for the production of modified versions of
the toxins. However, the production of multiple analogs or
large quantities for automated application systems or preclinical
treatment studies is costly, as is the production of large quantities
of isotopically enriched samples for high resolution NMR
spectroscopy studies or metabolic flux analysis (Antoniewicz,
2015). Chemical synthesis is also tedious if done manually and
requires special equipment and experience that is not typically
found in molecular biology laboratories. More generally, in the
case of larger peptides (>40 aa), the yield from chemical synthesis
is typically low. Finally, certain native peptides are inherently
difficult to produce synthetically.
Venom-peptide production in heterologous expression
systems might provide an efficient and economical alternative
to chemical synthesis for molecular biology laboratories (Klint
et al., 2013). It might also be suitable for large scale commercial
toxin production. In the current study, we adapted an Escherichia
coli periplasmic expression system (Klint et al., 2013) for
the production of 4/7 α-conotoxin TxIA and three analogs.
Unexpectedly, the functional and structural characterization of
the expressed analogs indicated that they adopt a fold different
from the native peptide (i.e., a 1–4, 2–3 “ribbon” rather than
a 1–3, 2–4 “globular” disulfide conformation). These data
demonstrate the need for careful structural analysis and confirm
earlier findings that non-native folds could still be active. As
an explanation for this activity and a basis for future structural
studies, we provide the first NMR solution structure of a 4/7
α-conotoxin ribbon isomer and propose a binding mode for
this peptide at the α7 nAChR. This information might be
useful for the design of new lead structures based on the ribbon
α-conotoxin scaffold.
MATERIALS AND METHODS
Preparation of Plasmids
A nucleotide sequence encoding a tobacco etch virus (TEV)
protease recognition site (ENLYFQG) followed by [R5N,I9H]
TxIA and including KpnI and SacI restrictions sites at the 5′ and
3′ ends, respectively, was optimized for expression in E. coli and
assembled from synthetic oligonucleotides (Life Technologies).
This construct was cloned in-frame to an 5′ His6-maltose binding
protein (MBP) sequence into the pLICC_D168 vector (Anangi
et al., 2012) using KpnI and SacI cloning sites. The conserved
N-terminal glycine residue of the conotoxin sequence forms the
last amino acid of the TEV protease recognition site and thus,
upon cleavage, produces a native N-terminus in the conotoxin.
Plasmids for production of TxIA as well as single mutated
R5D and R5N analogs were obtained from this construct by
site-directed mutagenesis. The sequences of all plasmids were
confirmed by Sanger sequencing.
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Recombinant Expression of TxIA
Analogs in E. coli
α-Conotoxin expression in E. coli was performed using a
previously described method (Anangi et al., 2012; Klint et al.,
2013). BL21 strains of E. coli were transformed with the respective
plasmids using a standard heat shock protocol. Five colonies
were selected to inoculate 5 ml culture medium (Luria-Bertani
plus ampicillin) and grown at 37◦C until the optical density
(OD600) reached 1.0. To determine optimal conditions for toxin
expression, 4 ml × 1 ml samples of each culture were then
diluted and grown again in 5 ml cultures until an OD of 0.6–
0.8 was reached. Then heterologous protein expression was
induced with IPTG. In doing so, culturing at 16◦C and 37◦C and
induction with 0.5 and 1.0 mM IPTG were performed and protein
expression in induced and non-induced cultures was compared
after 4 or 12 h by SDS-PAGE analysis of a cell pellet from 500 µl
of culture medium. The clone with the highest protein expression
was selected and used to start 1–2 l cultures (from 50 to 100 ml
precultures), which were then grown at 37◦C with shaking at
∼220 rpm. After reaching an OD of 0.6–0.8, toxin expression was
induced with 1 mM IPTG and cultures were grown overnight at
16◦C. Cultures were then centrifuged (15 min at 10,500 g) and
bacterial pellets frozen at−80◦C.
SDS-PAGE Analysis
500 µl of culture was centrifuged [5 min, 3,381 g (6,000 rpm)
in a desktop centrifuge] and cell pellets were supplemented
with 30 µl SDS running buffer and 30 µl 3× loading buffer.
After heating (10 min at 95–100◦C), 30 µl of the solubilized
cells were separated on a 10% SDS-PAGE gel under reducing
conditions (5% β-mercaptoethanol in the sample). To control
the purification and cleavage process, equivalent volumes (30–
200 µl) of lysate, flow-through, eluate, and cleaved sample were
supplemented with SDS running buffer to obtain 200 µl. After
addition of 200 µl 3× SDS running buffer, 50 µl of each sample
were separated using SDS-PAGE.
Recombinant Peptide Purification and
Cleavage
Cell pellets were resuspended in 50 ml equilibration buffer
(TN: 25 mM Tris-HCl, 300 mM NaCl, pH 7.0) and lysed
in a constant-pressure cell disrupter (27 kpsi, TS Series Cell
Disrupter, ConstantSystems, Ltd., Daventry, United Kingdom).
After centrifugation (4◦C, 30 min, 44,267 g), the supernatant was
diluted with an equal volume of modified TN buffer (40 mM
Tris-HCl, 400 mM NaCl, pH 8.0), supplemented with DNAse
(1 µg/ml lysate) and incubated for 30 min with 5 ml Ni-NTA
Superflow resin (Qiagen Pty, Ltd., Chadstone, VIC, Australia)
in a gravity-fed column. The column was washed with 50 ml
TN buffer containing 15 mM imidazole and then the His6-
MBP-TxIA fusion protein was eluted with 3 × 10 ml (each
time 30 min) TN buffer containing 400 mM imidazole. The
flow-through was concentrated to 5 ml (Amicon Ultra 30K
filter) and diluted with 5 ml TN buffer. TxIA peptide was
liberated from the fusion protein by cleavage overnight at room
temperature using ∼100 µg TEV protease. In order to maintain
TEV protease activity, reduced/oxidized glutathione were added
at a ratio of 1:5 w/w.
Recombinant Peptide Purification by
HPLC
The protease-cleaved samples were acidified with trifluoracetic
acid (TFA), centrifuged (10 min at 6,762 g) and filtered (Millipore
ultrafree MC 0.2 µm) to remove protein precipitates. Then 50%
acetonitrile (ACN) was added to a final concentration of 5%
ACN and the peptides were separated on a C18 semi-preparative
reversed-phase (RP) HPLC column (Vydac protein/peptide C18
column Cat# 218TP1010) on a Shimadzu Prominence HPLC
system (Shimadzu, Rydalmere, NSW, Australia). The following
linear gradients of solvent B (90% ACN, 0.043% TFA in water)
in solvent A (0.5% TFA in water) were used at a flow rate
of 3 ml/min: 5% B for 10 min, then 5–35% B for 30 min
followed by 35–80% B over 5 min and 80% B for another 7 min.
Absorbance was determined at 214 and 280 nm and collected
fractions were lyophilized and stored at −20◦C. The fractions
containing the correct peptide masses as determined by matrix-
assisted laser desorption/ionization mass spectrometry (MALDI
MS) were then subjected to another HPLC fractionation using a
hydrophilic interaction liquid chromatography (HILIC) column.
Samples were dissolved in 95% solvent B and injected into a
VisionHT HILIC column (5 µm particle size, 150 mm× 4.6 mm;
Grace, Columbia, MD, United States) at a flow rate of 1 ml/min.
The same solvents as during the RP-HPLC fractionation were
used with the following linear gradients: 95% solvent B for
the first 3 min, then 95–75% B over 20 min. Absorbance was
determined at 214 and 280 nm and the molecular masses of the
peptides determined using MALDI MS.
Analysis by Liquid
Chromatography/Mass Spectrometry
Solvents used for LC/MS were of HPLC-grade. Recombinant
peptide masses were determined by MALDI time-of-flight
(TOF) MS using a 4700 Proteomics Bioanalyzer model
(Applied Biosystems, Carlsbad, CA, United States). Peptides
were dissolved in water and mixed 1:1 (v/v) with α-cyano-4-
hydroxycinnamic acid matrix (7 mg/ml in 50% ACN, 5% formic
acid) and mass spectra acquired in positive reflector mode. All
reported masses are for the monoisotopic [M+H+] ions.
For analysis of the synthetic TxIA ribbon analog, the
LC/MS system consisted of an Waters Alliance 2695 HPLC
(Milford, OH, United States) coupled to a Micromass ZQ
mass spectrometer (electrospray ionization mode, ESI+). All
analyses were carried out using a Chromolith (Fontenay-sous-
Bois, France) HighResolution RP-18e column (4.6 mm× 25 mm,
15 nm–1.15 µm particle size). A flow rate of 3 ml/min and a
gradient of 0–100% solvent B over 2.5 min were used. Eluent
A was water/0.1% formic acid while eluent B was ACN/0.1%
formic acid. UV detection was performed at 214 nm. ESI mass
spectra were acquired using a solvent flow rate of 200 µl/min.
Nitrogen was used for both the nebulizing and drying gas. Data
were obtained in a scan mode over the m/z range 100–1000 or
250–1500 in 0.7 s intervals. Fully folded synthetic ribbon TxIA
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was characterized using a Synapt G2-S high-definition MS system
(Waters, Corp., Milford, MA, United States) equipped with an
ESI source. Chromatographic separation was carried out at a flow
rate of 0.4 ml/min on a Acquity H-Class ultrahigh performance
liquid chromatography (UPLC) system (Waters, Corp., Milford,
MA, United States), equipped with a Kinetex C18 100A column
(100 mm × 2.1 mm, 2.6 µm particle size) from Phenomenex
(France). The mobile phase consisted of water (solvent A) and
ACN (solvent B) with both phases acidified by 0.1% (v/v) formic
acid. Mass spectra were acquired in the positive ionization mode.
Two-Electrode Voltage Clamp (TEVC)
Electrophysiology
cDNAs encoding rat nAChR subunits were provided by J. Patrick
(Baylor College of Medicine, Houston, TX, United States) and
subcloned into the oocyte expression vector pNKS2 (Gloor et al.,
1995). cRNA was synthesized with the SP6 mMessage mMachine
Kit (Ambion, Austin, TX, United States) and adjusted to a
concentration of 0.5 µg/µl. nAChR subunit RNAs were mixed
in the ratios 1:1 (α3/β2) or 5:1 (α4/β2). Xenopus laevis (Nasco
International, Fort Atkinson, WI, United States) oocytes were
injected with 50 nl aliquots of cRNA (Nanoject automatic oocyte
injector, Drummond Scientific, Broomall, PA, United States).
Antagonist concentration-response curves were measured as
described previously (Dutertre et al., 2005; Beissner et al., 2012)
in ND96 (96 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM
MgCl2, and 5 mM HEPES at pH 7.4). In brief, current responses
to acetylcholine were measured at room temperature 1–6 days
after cRNA injection and recorded at −70 mV using a Turbo
Tec 05X Amplifier (NPI Electronic, Tamm, Germany) and Cell
Works software. A standard concentration of 100 µM ACh or
nicotine was used to activate the αβ combinations and the α7
nAChR, respectively. A fast and reproducible solution exchange
(<300 ms) was achieved with a 50-µl funnel-shaped oocyte
chamber combined with a fast vertical solution flow fed through a
custom-made manifold mounted immediately above the oocyte.
Agonist pulses were applied for 2 s at 4-min intervals. Following
1 min of perfusion directly after the agonist application, peptides
were applied in a static bath for 3 min. IC50 values were
calculated from a non-linear fit of the Hill equation to the data
(Prism version 6.0; GraphPad Software, Inc., San Diego, CA,
United States). Data are presented as means ± SEM from at
least three oocytes.
Chemical Synthesis of Ribbon and
Native α-TxIA
ACN, TFA, dimethylformamide (DMF), N,N-
diisopropylethylamine (DIEA), triisopropylsilane (TIS),
dichloromethane (DCM), piperidine and other reagents
were obtained from Sigma-Aldrich (St. Louis, MI, United States)
or Merck (Darmstadt, Germany) and used as supplied. Fmoc
L-amino acid derivatives and 1[bis(dimethylamino)methylene]-
1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate
(HATU) were purchased from Iris Biotech (Marktredwitz,
Germany). AmphiSpheres 20 HMP resin (0.6 mmol/g) was
purchased from Agilent Technologies (Les Ulis, France). The
side chain protecting groups for amino acids are t-Bu for Asp
and Ser; Acm for Cys9,14; Trt for Cys1,15 and Asn; Pbf for Arg.
Ribbon α-TxIA was manually synthesized using the Fmoc-based
solid-phase peptide synthesis technique on a VWR (Radnor,
PA, United States) microplate shaker. All Fmoc amino acids
and HATU were dissolved in DMF to reach 0.5 M. Chain
elongation was performed step by step using 0.2 mmol of
AmphiSpheres 20 HMP resin. Fmoc deprotection was performed
with 20% piperidine in DMF two times, each for 1 min at room
temperature, then the resin was washed three times with DMF.
Each Fmoc-protected amino acid (5 eq.) was coupled twice in
the presence of HATU (5 eq.) and DIEA (10 eq.) in DMF at room
temperature for 2 min. After completion of the coupling reaction,
the resin was sequentially washed twice with DMF. Cleavage
of peptide from the resin and removal of side-chain protecting
groups were carried out using 20 ml of a solution containing
TFA/TIS/H2O (95:2.5:2.5, v/v/v) for 3 h at room temperature.
After the resin was removed by filtration and washed with DCM,
the DCM and TFA were removed under vacuum and cold diethyl
ether was added to precipitate the peptide. Crude peptide was
purified by preparative RP-HPLC, and its purity determined
using LC/ESI-MS. Trt groups were removed during the cleavage
step while the Acm protective groups are resistant to cleavage
conditions. A two-step oxidation procedure was then carried out.
Briefly, the first disulfide bridge was formed from free cysteines
with the use of 2,2′-dithiopyridine (DTP) (Maruyama et al.,
1999; Giribaldi et al., 2018) and then the second disulfide bridge
was formed by concomitant deprotection and oxidation of the
Acm groups with the use of iodine (Gyanda et al., 2013). The
fully folded peptide was purified by analytical RP-HPLC and
purity confirmed by high-resolution mass spectrometry During
the purification process, the ribbon form of α-TxIA appears as
a broad peak on analytical RP-HPLC (containing unseparable
major and a minor peaks), which is possibly due to slow cis–trans
interconversion of the proline residues.
Globular TxIA was synthesized as described
(Dutertre et al., 2007).
Synthetic Peptide Purification
Preparative RP-HPLC was run on a Gilson PLC 2250
HPLC system (Villiers le Bel, France) using a preparative
column (Waters DeltaPak C18 Radial-Pak Cartridge, 100 Å,
40 mm × 100 mm, 15 µm particle size, flow rate 50.0 mL/min).
Buffer A was 0.1% TFA in water, and buffer B was 0.1% TFA
in ACN. Fully folded synthetic TxIA ribbon was purified on a
UltiMate 3000 UHPLC system (Thermo Fischer Scientific) using
an Kinetex C18 100 A column (100 mm × 2.1 mm, 2.6 µm
particle size) from Phenomenex (France). Buffer A was 0.1%
formic acid in water, and buffer B was 0.1% formic acid in ACN.
NMR Spectroscopy Analysis
Secondary Shifts of Recombinant Peptides
Peptides were dissolved in 90% H2O/10% D2O (Cambridge
Isotope Laboratories) at a concentration of 1 mg/ml and pH
∼3.6. Spectra were recorded on a Bruker Avance 600 MHz
spectrometer at 7◦C and referenced to 4,4-dimethyl-4-
silapentane-1-sulfonic acid (DSS) at 0 ppm. Standard Bruker
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pulse programs were used for all two-dimensional spectra.
Excitation sculpting with gradients was used to achieve
water suppression for TOCSY and NOESY experiments
(Hwang and Shaka, 1995). NMR experiments included TOCSY
(Braunschweiler and Ernst, 1983) using a MLEV-17 spin lock
sequence with a 80 ms mixing time, NOESY (Jeener et al., 1979)
with a 200 ms mixing time, 1H- 13C HSQC (Palmer et al., 1991)
and 1H-15N HSQC (Palmer et al., 1991). Spectra were recorded
with 4096 data points in the F2 dimension and 512 increments
in the F1 dimension for TOCSY, and NOESY experiments,
2048 × 240 for 1H-13C HSQC and 2048 × 128 for 1H-15N
HSQC data points in the F2 dimension and increments in the F1
dimension, respectively. The t1 dimension was zero-filled to 1024
real data points, and the F1 and F2 dimensions were multiplied
by a sine-squared function prior to Fourier transformation.
All spectra were processed using TopSpin 2.1 (Bruker) and
assigned with CcpNmr Analysis (Vranken et al., 2005) using the
sequential assignment protocol (Wüthrich, 1986). Secondary
shifts were calculated using the random coil values reported by
Wishart et al. (1995).
Structure of Synthesized Ribbon TxIA
A 2D NOESY spectrum was acquired with a mixing time
of 200 ms at 7◦C and interproton distance constraints were
calculated from the relative intensities of NOE cross-peaks.
Predictions of φ and ψ backbone angles were performed with
TALOS-N (Shen and Bax, 2013). Distance restraints for the
disulfide bonds defined by the regioselective synthesis were used
in the structure calculations. The ANNEAL function in CYANA
was used to perform 10,000 steps of torsion angle dynamics
to generate an initial ensemble of 100 structures from which
the 20 structures with the lowest penalty function values were
chosen for analysis. Several rounds of structure calculations were
performed to resolve distance and angle constraint violations.
Using protocols from the RECOORD database (Nederveen
et al., 2005), an ensemble of 100 structures was subsequently
calculated with CNS (Brünger et al., 1998) using the force field
distributed with Haddock 2.0 (Dominguez et al., 2003) and
further refined in a water shell (Linge and Nilges, 1999). A set
of 20 structures with the lowest energy and no NOE violations
greater than 0.2 Å or dihedral-angle violations greater than 3◦
was selected for MolProbity analysis (Williams et al., 2018). The
structures were visualized and figures generated using MOLMOL
(Koradi et al., 1996).
Molecular Modeling
Molecular models of the complexes between the ligand-binding
domain of α7 nAChR and conotoxins were prepared by
homology modeling and then refined using either molecular
dynamics (MD) simulations or the ToxDock method (Leﬄer
et al., 2017). The molecular models are provided along
the manuscript in Supplementary Material Data Sheet 1.
Homology models were constructed using Modeler 9v18 (Sali
and Blundell, 1993) using three templates: (i) the NMR solution
structure of ribbon TxIA (this study); (ii) the α4/α4 interface
of the cryo-electron microscopy structure of the human α4β2
nAChR (PDB 6CNK) (Walsh et al., 2018); and (iii) the
crystal structure of the complex between globular conotoxin
[A10L]TxIA and the Aplysia californica acetylcholine binding
protein (AChBP, PDB 2UZ6) (Dutertre et al., 2007). A 100
models were generated for each system and the model with
the lowest DOPE score (Shen and Sali, 2006) was selected for
further refinement.
Refinement With MD Simulations
Homology models of the interaction of ribbon deamidated
TxIA, [R5D] ribbon TxIA, and [R5N] ribbon TxIA with rat
α7 nAChR were obtained by homology modeling as described
above. These initial models were then minimized and subjected
to MD simulations in Gromacs 2018 using the Ambr99SB-
ILDN forcefield (Lindorff-Larsen et al., 2010). The systems were
embedded in a cubic box of 11 nm × 11 nm × 9 nm and
solvated with ∼32,000 water molecules and several sodium ions
to neutralize the systems. The system was then energy minimized
using 10,000 steps of steepest gradient and submitted to an
equilibration protocol during which position restraints on the
receptor and toxin were progressively released; the constraints
on the toxin atoms were released first over 6 ns, and the
constraints on the receptor then over 2.4 ns. The systems were
then simulated unrestrained for 50 ns. Long-range electrostatic
interactions were computed using particle mesh Ewald with
default parameters in Gromacs. All bonds involving hydrogens
were constrained with the LINCS algorithm, and the time step
of the simulation was set to 2 fs. The V-rescale thermostat (Bussi
et al., 2007) was used to maintain the temperature at 27◦C and the
pressure was maintained at one atmosphere using the Berendsen
isotropic pressure coupling. The short range electrostatic and
Van der Waals cutoffs were both set at 1 nm. The binding free
energy of each system was then computed using the MMPB/SA
method (Miller et al., 2012) as implemented in Amber18 by
analyzing 10 frames extracted every ns from the last 10 ns of the
unrestrained simulation.
ToxDock Refinement
The ToxDock (Leﬄer et al., 2017) refinement and energy
computations were carried out using the online server Rosie
(Lyskov et al., 2013). Briefly, the Rosetta fast relax protocol
(Tyka et al., 2011) was used to generate 200 alternative models
representing small structural fluctuation of the complex. The
50 models with lowest Rosetta total score were submitted for
a FlexPepDock refinement (Raveh et al., 2010), generating 500
alternative binding modes of the peptide bound to the receptor
and computing the reweighted docking Rosetta score. The
average of the 25 lowest reweighted score was taken as the
relevant to the binding score of the complex, as previously
described (Leﬄer et al., 2017). The Talaris2013 energy function
was used for all Rosetta computations (Leaver-Fay et al., 2013).
RESULTS
Efficient Production of Recombinant
TxIA Analogs
Like most characterized 4/7 α-conotoxins, TxIA preferentially
targets α7 and α3β2 nAChRs with nanomolar potency but has
no detectable activity at the α4β2 subtype (Dutertre et al.,
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2007). Whereas some α3β2-selective conotoxins such as MII
(Azam and McIntosh, 2009) also have high potency at the
closely related α6β2 receptor, no conotoxin that selectively
targets the α4β2 nAChR has been yet identified, and only a
few 4/7 α-conotoxins, such as MII (Cartier et al., 1996), GID
(Nicke et al., 2003), and GIC (McIntosh et al., 2002) have
been shown to block this receptor, albeit at high nanomolar
or micromolar concentrations. Therefore, one aim of this
study was to identify amino acid side chains that could
prevent conotoxin binding to α4β2 receptors by investigating
if TxIA could be modified to obtain a conotoxin with at
least weak activity at α4β2. To this end, we compared the
amino acid sequence of TxIA with those of MII, and GID and
selected two positions, 5 and 9, in which we substituted the
amino acid side chains (Figure 1A). Position 5 was previously
shown to be important for MII binding to α3β2 nAChRs
(Everhart et al., 2004).
The DNA sequences corresponding to TxIA and analogs were
optimized for expression in E. coli and fused N-terminally via
a TEV protease cleavage site to MBP (Figure 1B). Although
the consensus TEV protease cleavage site is ENLYFQ/S, the
protease also efficiently cleaves at ENLYFQ/G (Kapust et al.,
2002), which has the advantage that the N-terminal glycine
residue that is present in most α-conotoxins can be used
and remains after cleavage. Expression of the TxIA analogs
in form of a His6-MBP fusion protein was done to target
the construct to the E. coli periplasmic space where the
disulfide bond folding machinery of the bacterium (i.e., the Dsb
proteins) is located and the oxidative environment is favorable
for conotoxin folding and disulfide bond formation. Upon
transformation of E. coli with these constructs and induction with
IPTG, the respective fusion proteins represented the dominant
proteins produced and they could be successfully purified and
cleaved as indicated by the size shift of the MBP fusion
construct (Figure 1C and Supplementary Figure S1A). Further
purification by RP-HPLC revealed one dominant peak for each of
the TxIA analogs (Figure 2A and Supplementary Figure S1B).
The corresponding fractions contained the calculated mass
of the fully oxidized peptides (Figure 2C) and turned out
to represent the sole functional fractions when tested by
TEVC electrophysiological analysis on α3β2 nAChRs expressed
in Xenopus laevis oocytes (Figure 2B and Supplementary
Figure S1C). The obtained yields were 1–2 mg of conotoxin
per liter of culture. An additional HILIC-HPLC purification
step was employed (Supplementary Figure S2) to obtain
pure recombinant peptides as determined using MALDI-MS
(Figure 2C and Supplementary Figure S2). These purified
peptides were then used for preparation of concentration
response curves (see below). The double mutant [R5N,I9H] was
not further analyzed.
Electrophysiological Analysis of
Recombinant TxIA Analogs Reveals
Strongly Reduced Potency
We compared the potencies of the repurified expressed peptides
TxIA, [R5D]TxIA, and [R5N]TxIA with synthetic TxIA at
FIGURE 1 | Recombinant production of TxIA. (A) Amino acid sequence
alignment of native and mutant analogs of TxIA with α-conotoxins that show
some affinity to α4β2 nAChRs, and their respective IC50 values (for references
see, Dutertre et al., 2017). Italics indicate values at human nAChR isoforms.
Conserved cysteine residues are shown in boxes. The number of residues
between the cysteines defines the 4/7 α-conotoxin subfamily. Residues in MII,
GID, GIC, PeIA that differ from TxIA are shown in bold red. Mutated TxIA
residues in position 5 and 9 are also highlighted in red. IC50 values refer to
studies using Xenopus laevis oocytes. (B) Schematic representation showing
the design of the pLic-MBP plasmid used for periplasmic expression of
disulfide-rich peptides in Escherichia coli. The construct encodes a His6 tag
for affinity purification, followed by a MBP fusion tag for solubility and a TEV
protease recognition site between the MBP and the TxIA sequences.
(C) Coomassie Blue stained SDS-PAGE gels showing samples of the fusion
construct obtained during different steps of recombinant peptide production
and purification. The difference in molecular mass between the concentrated
eluate before (second last lane) and after (last lane) TEV protease cleavage
indicates cleavage of TxIA from the His6-MBP.
oocyte-expressed α3β2, α4β2, and α7 nAChRs. Unlike the E. coli-
expressed α-conotoxins, but like native TxIA, the synthetic
TxIA was C-terminally amidated. Not only were none of the
analogs active at the α4β2 nAChR but all recombinant peptides
showed a marked drop in potency compared to synthetic TxIA
(Figure 3A). Preparation of full concentration-response curves
revealed that in comparison to synthetic TxIA, which yielded
IC50 values of ∼5 nM and 2 µM at α3β2 and α7 nAChRs,
respectively, the recombinant TxIA was about 100- and 50-
fold less active at α3β2 and α7 nAChRs (Figure 3B and
Table 1). Interestingly, the potency decrease at the α7 receptor
was almost completely reversed when the arginine residue in
position 5 was substituted by an aspartic acid residue, but not
when an asparagine residue was introduced in this position.
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FIGURE 2 | Purification of TxIA and mutant (R5D, R5N) analogs. (A) RP-HPLC chromatograms showing first step RP-HPLC fractionation with the peaks highlighted
in red containing the correct molecular mass as determined by MALDI MS. (B) Antagonistic activity of the purified toxin peak (i.e., the red peak from A) at α3β2
nAChRs. Oocytes were clamped at –70 mV and 100 mM ACh were used to activate α3β2 nAChRs. (C) MALDI MS traces after second step HILIC fractionation of
the purified TxIA and analogs (red colored fractions in Supplementary Figure S2) indicate the monoisotopic molecular masses of the purified toxins. All reported
masses are for [M + H]+ ions.
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Consequently, whatever caused the decrease in activity of the
recombinant TxIA, lack of amidation, proline isomerization,
and/or misfolding of the peptide, could be compensated by
changes in the primary structure.
Structural Analysis of Recombinant TxIA
Analogs Confirms the Preferential
Formation of Ribbon Isomers
Because all of the recombinant peptides showed at least some
potency at α3β2 nAChRs and peptides in the other fractions
turned out to be inactive or less active, we assumed that
the dominant peaks corresponded to the native (i.e., globular)
conformation of the peptides. However, because of the strong
potency decrease that is clearly higher than the 2- or 5-fold
potency reduction of non-amidated AnIB analogs at α3β2 and
α7 nAChRs, respectively (Loughnan et al., 2004) we considered
the possibility of non-native disulfide linkage in the E. coli-
expressed TxIA analogs. To test this hypothesis, NMR structural
analysis was performed. The three expressed TxIA analogs
yielded well-dispersed 1H NMR resonances, implying that they
adopt ordered structures in solution. These peptides were further
analyzed using two-dimensional NMR so that the data could
be compared to published data for Pn1.2, which has a related
sequence and where NMR data for each of the disulfide isomers is
available (Carstens et al., 2016). To assign the spectra, Hα-NHi+1
connectivities obtained from NOESY spectra were used in the
sequential assignment of individual spin systems determined
from the TOCSY spectra. For all of the TxIA analogs, sequential
Hα-NHi+1 connectivities were observed for the entire peptide
chain, except at the Pro residues that lack backbone amide
protons. Analysis of the NOE data and the Cδ chemical shifts
of Pro7 indicated that this proline is in the cis confirmation
(Schubert et al., 2002). Analysis of secondary shift data can
supply information on secondary structural elements of peptides
(Wishart et al., 1991), and is useful for comparing structural
frameworks in disulfide-rich peptides. Figure 4B shows the
Hα secondary shifts for TxIA and compares these values with
previously published secondary shifts for the three possible
disulfide isomers of Pn1.2. The Hα secondary shifts for the
TxIA most closely resemble those of the ribbon isomer of
Pn1.2, especially in the N-terminal region, which suggests that
the expressed TxIA is in the ribbon form. Furthermore, a
comparison of the secondary shifts for each expressed TxIA
analog (Figure 4A) and synthetic ribbon TxIA (see below and
Supplementary Figure S3C) reveals that they are almost identical
and all four peptides form the same disulfide isomer. Most of the
secondary shifts for the TxIA analogs vary within the ± 0.1 ppm
range that is consistent with a random coil structure, however
residues 9–11 have secondary shift values more negative than
−0.1 ppm, suggesting this region has some helical character. Our
structural and functional characterization of the TxIA analogs
is in agreement with data from Wu et al. (2014), where an 80-
fold potency reduction (IC50 of 5.4 to 430 nM) of synthesized
ribbon TxIA was observed at α3β2 nAChRs, which corresponds
well to the 100-fold reduction found in our study. Importantly,
this analysis further confirmed the purity of the expressed toxins
as similar retention times for globular and ribbon TxIA have been
described (Wu et al., 2014).
Solution Structure and Potential Binding
Mode of the Ribbon Isomer of TxIA
α-Conotoxins are generally considered to be weakly active or
inactive if they are folded in non-native conformations such as
“ribbon” or “bead” disulfide isomers. However, in case of the
4/6 conotoxin AuIB, the ribbon isomer turned out to be more
potent at α3β4 nAChRs than the globular form and seemed
to bind to the orthosteric binding site (Grishin et al., 2010).
Likewise, the ribbon form of the 4/3 α-conotoxin ImII was found
to compete with binding of its natively folded isomer at α7
nAChRs and also bound to an additional binding site at Torpedo
nAChRs (Kasheverov et al., 2009). For AuIB, a binding mode
has recently been defined in detail (Wu et al., 2018). However,
no ribbon 4/7 α-conotoxin structure has been determined to
date (Kaas et al., 2012). Inspired by the fact that ribbon isomers
of some conotoxins can competitively block ACh binding and
that TxIA potency at the α7 nAChR could be improved by the
substitution R5D, we set out to determine the structure of the
ribbon conformer of TxIA and its binding mode at α7 nAChR. To
this end, a non-amidated ribbon isomer of TxIA was synthesized
(Supplementary Figure S3) by a two-step oxidation method and
its NMR structure calculated using CYANA 3.0 (Güntert et al.,
1997) and refined in CNS (Brünger et al., 1998) using TALOS-N
(Shen et al., 2009) derived dihedral angle restraints, and hydrogen
bond restraints derived from D2O exchange experiments.
The structural statistics for the ensemble of the 20 lowest
energy structures for each isomer are shown in Table 2, and
the structural ensemble of the 20 representative structures
are shown in Figure 4C (left). The mean structure of the
ribbon isomer of TxIA (Figure 4C, right), although well-
defined (backbone RMSD = 0.58 ± 0.3 Å), possesses no defined
secondary structure elements. However, several of the structures
in the ensemble have a 310-helical segment spanning residues
Cys8 to Asn11, which is generally consistent with the Hα
secondary shift data. Furthermore, loop 1 of ribbon TxIA (Cys2–
Cys8) is well-defined (backbone RMSD = 0.21 ± 0.07 Å)
and resembles loop 1 of globular TxIA, but loop 2 (Cys8–
Cys16) is less well-defined (backbone RMSD = 0.48 ± 0.29 Å)
and adopts a conformation that is distinct from loop 2 of
globular TxIA. Analysis of the electrostatic surface features in
MOLMOL reveals negatively charged regions on opposite faces,
corresponding to the C-terminal acid and the sidechain of
Asp14, and a positively charged region due to the sidechain
of Arg5 and N-terminus (Figure 4D). This structure was
subsequently used to probe the binding mode in a MD-
refined model and a model based on the recently defined
ToxDoc application.
Molecular Modeling
Binding Modes in the ToxDock- and MD-Refined
Models
The binding modes of ribbon TxIA at the α7 nAChR generated
by MD simulations and by ToxDock are globally similar in
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FIGURE 3 | Potency comparison of synthesized amidated and expressed non-amidated TxIA on nAChR subtypes. (A) Reduction of control responses activated by
100 µM ACh or nicotine (in case of α7 nAChR) by 1 µM synthetic (syn) or recombinant TxIA (rec = wild type; R5D and R5N amino acid substitutions) at the indicated
nAChR subtypes expressed in Xenopus oocytes and measured using TEVC electrophysiology. (B) Concentration-response curves for synthetic and recombinant
TxIA at α3β2 (left) and α7 (right) nAChRs. Error bars represent the SEM from at least three recordings [except for high (>10 µM) concentrations of synthetic peptides,
where not enough material was available]. Oocytes were clamped at –70 mV. 100 µM ACh or 100 µM nicotine were used to activate α3β2 and α7 receptors,
respectively.
TABLE 1 | IC50 values and Hill coefficients (nH) for synthetic TxIA and recombinant TxIA, [R5D]TxIA, and [R5N]TxIA at rat α3β2 and α7 nAChRs.
α3β2 α7
IC50 (nM) nH IC50 (nM) nH
Synthetic 4.6 −0.93 1812 −1,23
TxIA (3.6 to 5.8) (−1.15 to −0.71) (1555 to 2111) (−1,52 to −0,99)
Synthetic 928 −1.14 ≈ 200.000 ND
rTxIA (810 to 1064) (−1.3 to −0.98)
Recombinant 470 −1.54 ≈ 200.000 ND
TxIA (432 to 512) (−1.73 to −1.35)
Recombinant 3543 −1.38 2915 −1.24
[R5D]TxIA (3166 to 3965) (−1.58 to −1.17) (2406 to 3532) (−1.53 to −0.96)
Recombinant 1834 −1.36 ND ND
[R5N]TxIA (1704 to 1974) (−1.49 to −1.24)
Numbers in brackets are 95% confidence intervals. ND means not determined. Italic numbers are estimates.
terms of the orientation of the toxin in the binding site,
with some molecular interactions shared between the two
models but also a range of interactions that are different
(Figures 5A,B). Pro6 in Loop 1 of wild-type or variant ribbon
TxIA occupies a similar position in the models as P6 of the
globular TxIA in the TxIA/AChBP experimental structure. P6 is
an important determinant of the interaction of α-conotoxins as
it is embedded in the aromatic box, which is at the bottom of
the orthosteric binding site and is recognized by acetylcholine.
Another important conserved feature of the interaction of
globular α-conotoxin with AChBP is the stacking between the
vicinal disulfide bridge of the C-loop with the first disulfide
bond of the α-conotoxin. The MD-refined model displays this
interaction but not the ToxDock-refined model in which the side
chain of D14 stacks between the two disulfide bonds. This is
interesting because the conformation of toxin in the two models
is globally preserved (the backbone RMSD of the toxins in the
two models is only 1.5 Å). The binding mode in the ToxDock
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FIGURE 4 | Structural analysis of the ribbon disulfide isomers of TxIA and analogs. (A) Hα secondary shift values for recombinant TxIA (open circles), [R5D]TxIA
(squares), [R5N]TxIA (triangles), and synthetic ribbon TxIA (closed circles) at 7◦C. Please note that due to the identity of the peptides, the secondary shifts overlap
and most data points (filled circles) are hardly visible (B) A comparison of the Hα secondary shifts for ribbon TxIA (black) with the Hα secondary shifts of ribbon (red),
globular (green) and beads (blue) isomers of Pn1.2. The values for ribbon TxIA most closely match those of ribbon Pn1.2, especially in the N-terminal region. (C) Left
panel: ensemble of the 20 lowest energy structures for ribbon TxIA. The peptide backbone is in blue and the disulfides are in gold. Right panel: the mean structure of
ribbon TxIA calculated from the ensemble. The structure is shown in ribbon format with disulfide bonds in ball and stick. The N- and C-termini are indicated and the
cysteines are labeled. (D) Electrostatic surface of ribbon TxIA (PDB ID 6OTA) highlighting the negatively charged regions (red) corresponding to the C-terminal acid
and Asp14, and the positively charged regions (blue) corresponding to the N-terminus and the side chain of Arg5.
model is slightly tilted compared to the MD model, and this leads
to a change in reorientation of the N-terminus (from G1 to S4)
and of Loop 2 in general. The conformation of the wild-type
and variants in the context of the binding site was highly stable,
with a backbone RMSD < 1.5 Å and on average 1 Å from the
initial homology model. The binding modes of the toxins were
also similarly stable, with Loop 1 being highly rigid and Loop 2
undergoing larger, albeit small, conformational fluctuation. The
binding mode of the ToxDock model was not sampled during
the MD refinement, and they should therefore be considered as
two hypothetical binding modes. The location and interaction
of position 5 in the models of the wild-type TxIA are similar,
and the interactions of this position in TxIA and variants will
now be described using the MD-refined models (Figures 5C–E).
Supplementary Figure S4 describes the interaction as suggested
in the ToxDock-refined models.
Molecular Interactions of Position 5
TxIA R5 is located in Loop 1 and establishes a salt-bridge
with α7 D196 in the wild-type model, similar to the interaction
of globular TxIA R5 with AChBP D197 in the TxIA/AChBP
crystal structure. The model also suggests the proximity of two
principal subunit basic residues, α7 R185 and K144, which
could create an unfavorable electrostatic environment for Arg
5. In contrast, the model of ribbon [R5D]TxIA shows that D5
establishes a salt bridge with α7 R185. In the ToxDock model
of [R5D]TxIA, D5 also forms a salt-bridge but with α7 K144.
Position 5 therefore seems to be better suited for a negatively
charged residue than a basic residue. Asn and Asp are isosteric,
but Asn is neutral whereas Asp is negatively charged. In contrast
to [R5D]TxIA, the mutant displaying an Asn at position 5, i.e.,
[R5N]TxIA, has similar activity to the parent peptide, strongly
suggesting that the charge of the side chain at position 5 drives
the increase in activity at the α7 nAChR (Figures 5D,E). This
observation also suggests that the charge interactions of TxIA
R5 with the complementary subunit balanced out and do not
contribute to affinity. Interestingly, this analysis suggests that an
R5D substitution of the globular TxIA would increase affinity for
the α7 nAChR.
Mutational Energy Predictions
The interaction energies predicted by ToxDock were similar
for the three complexes, with the interaction energy of wild-
type ribbon TxIA in Rosetta units (RUs) being −592 for
TxIA, −594 for [R5D]TxIA, and −595 for [R5N] TxIA. The
mutational energies predicted by MMPB/SA suggest that the
[R5N] mutant should have increased affinity by −4 kcal/mol
compared to the parent peptide, while the [R5D] substitution
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FIGURE 5 | Molecular models of the binding modes of ribbon TxIA at the α7 nAChR: (A) MD-refined molecular model, (B) ToxDock refined molecular model, and
interaction of position 5 in the MD-refined model of (C) ribbon TxIA, (D) ribbon [R5N]TxIA, or (E) ribbon [R5D]TxIA. The last frame of the 50 ns MD simulation is
shown in (A). The model with the lowest re-weighted Rosetta score is shown in (B). The backbone of the receptor and peptides are shown using cartoon
representation [blue and wheat color for the principal (+) and complementary (–) subunits, respectively], the side chains of the toxins are shown as sticks (orange) and
the side chain of receptor residues located at less than 5 Å from the toxin are shown in stick representation. Hydrogen bonds are indicated by dashed black lines.
was predicted to decrease affinity by 13 kcal/mol. None of the
energy predictions therefore correlated with the experimental
IC50 values, possibly because the main determinants of the
affinity change involve evaluating the interaction of salt bridges
in a partially solvated environment in the vicinity of several
oppositely charged residues, which is challenging. Current force
fields still have difficulty in reproducing the strength of solvated
salt bridges (Ahmed et al., 2018). In addition, the estimation
of binding energy is highly dependent on the accuracy of the
three-dimensional structures of the complex. The incomplete
consensus between the ToxDock- and MD-refined models
suggest that these binding modes of ribbon α-conotoxins are
not accurate enough for predicting the impact of mutations
using score or energy computations. The determination of
an experimental structure of a ribbon conotoxin bound to
either AChBP or a nAChR should dramatically increase our
ability to predict the interaction of ribbon conotoxins and the
impact of mutations.
DISCUSSION
Here we describe for the first time the production of a
recombinant α-conotoxin (4/7 α-conotoxin TxIA and three
analogs) by expression in the periplasm of E. coli. We
characterized the structure of three of these recombinant toxins
and determined that, contrary to expectation, they adopt a ribbon
conformation, which is not the dominant disulfide connectivity
obtained during random oxidation of synthetically produced
α-conotoxins. Ribbon TxIA experienced a significant decrease
in activity at the α3β2 and α7 nAChRs, and we discovered
that the mutant [R5D]TxIA could rescue the activity at the α7
nAChR at a similar level to that of globular TxIA, possibly
because the location of position 5 in the α7 binding site
is more electropositive.
Expression of α-Conotoxins in Bacteria
So far, three α-conotoxins, the 4/7 α-conotoxins Vc1.1, LvIA, and
TxIB, have been recombinantly expressed (Singer et al., 2012;
Zhu et al., 2016; Yu et al., 2018). Vc1.1 was expressed in the
non-pathogenic Salmonella enterica serovar Typhimurium strain
LT2. It was fused via a TEV protease cleavage site to a flagellar
secretion substrate FlgM, enabling export of recombinant non-
flagellar peptides through the flagellum and into the surrounding
medium (Singer et al., 2012). No functional or structural data of
Salmonella-expressed Vc1.1 were provided in that study.
LvIA was expressed in tandem repeats of various lengths
in E. coli and purified from inclusion bodies which are
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TABLE 2 | Structural statistics for the final ensemble of 20 structures for the
ribbon isomer of TxIA with the highest overall MolProbity score.
Energies (kcal/mol)
Overall −475.3 ± 3.1
Bonds 6.51 ± 0.67
Angles 20.11 ± 2.48
Improper 9.21 ± 2.26
Van der Waals −36.82 ± 3.04
NOE 0.02 ± 0.01
cDih 0.98 ± 0.67
Dihedral 65.78 ± 0.89
Electrostatic −541 ± 6.3
MolProbity statistics
Clashes (>0.4 Å/1000 atoms) 14.3 ± 4.66
Poor rotamers 0.05 ± 0.22
Ramachandran outliers (%) 0.0 ± 0.0
Ramachandran favored (%) 85.5 ± 6.19
MolProbity score 2.29 ± 0.31
Residues with bad bonds 0.00 ± 0.00
Residues with bad angles 0.00 ± 0.00
Atomic RMSD (Å)
Mean global backbone 0.58 ± 0.26 (residues 1–16)
Mean global heavy 1.19 ± 0.37 (residues 1–16)
Distance Restraints
Intraresidue (| i-j| = 0) 35
Sequential (| i-j| = 1) 44
Medium range (1 < | i-j| < 5) 16
Long range (| i-j| > 5) 8
Hydrogen bonds 3
Total 106
Dihedral angle restraints
φ 11
ψ 8
χ1 9
Total 28
Violations from experimental restraints
Total NOE violations exceeding 0.3 Å 0
Total dihedral violations exceeding 3.00 0
generated during conventional recombinant protein expression
in E. coli (Zhu et al., 2016). To allow chemical cleavage
with cyanogen bromide, the individual peptide sequences
were linked by methionine residues, which resulted in the
N-terminal addition of a methionine residue to the cleaved
peptides. Using this procedure and folding by air oxidation,
a 18-fold decrease in activity from 9 to 160 nM was
observed for the recombinant peptide compared to synthetic
LvIA (Luo et al., 2014; Zhu et al., 2016). This decrease in
activity was suggested to be due to the additional N-terminal
methionine and/or the missing C-terminal amidation. The
latter would be in agreement with the 2- and 5-fold potency
reduction of non-amidated AnIB analogs at α3β2 and α7
subtypes respectively (Loughnan et al., 2004). However, the
disulfide connectivity of the E. coli-expressed LvIA was not
determined and our study of recombinant TxIA suggests
that alternative disulfide connectivity could also explain the
activity change.
In a more recent study from the same group (Yu et al.,
2018), monomeric TxIB was expressed in E. coli as a ketosteroid
isomerase (KSI)–TxIB(M)–His6–fusion protein. KSI was used to
help stabilize the peptide in inclusion bodies and the insoluble
KSI could be easily separated upon cleavage from the peptide.
A C-terminal methionine residue (M) had to be added to allow
subsequent release of the peptide from KSI and the His6-tag by
cleavage with cyanogen bromide. Interestingly, the recombinant
TxIB retained selectivity for α6β2 receptors and showed only a
moderate twofold decrease in potency. Based on these properties,
a globular fold was inferred because ribbon and bead isomers of
TxIB were reported to be inactive.
Encouraged by reports on bacterial expression of other toxins
and in an attempt to bypass the problem of aggregation in
inclusion bodies, we exploited a system that allows expression of
venom peptides in the form of periplasmic MBP fusion proteins.
The idea of using periplasmic expression is to hijack the disulfide-
bonding machinery in E. coli for producing natively folded
heterologous peptides (Klint et al., 2013). Here, intramolecular
disulfide bonds should form as the polypeptide chain exits the
reductive environment of the bacterial cytoplasm and enters
the oxidizing periplasmic environment. With a success rate of
75% based on the expression of 31 venom peptides (ranging
from 17 to 76 residues in length with 2–6 disulfide bonds) from
spiders, scorpions, sea anemone, and cone snails, this method
mostly produces correctly folded peptides (Klint et al., 2013).
However, the 25% of peptides that failed to express using this
method indicate that the folding machinery in E. coli is not always
a good surrogate for the mechanisms found in the venomous
organisms from which the respective peptides were sourced. In
the case of venom peptides from cone snails, the only other
peptide that was tried (and failed) in this expression system
was MVIA (Klint et al., 2013). In regard to TxIA, we could
also not produce any native (globular) isomer, as all of the
recombinant TxIA formed the ribbon isomer. In summary, for
the only two Conus venom peptides that have been investigated
so far, periplasmic expression in E. coli failed to produce the
native disulfide-bond isomer. However, additional data with
other Conus peptides is required to make a conclusion about the
general suitability of this system for producing natively-folded
cone snail venom peptides.
Does the Primary Structure Affect the
Folding?
One surprising finding was that all expressed variants eluted
in one dominant peak. In contrast to the present results and
in agreement with data on other α-conotoxins, chemically
synthesized and randomly oxidized α-conotoxin TxIA folds in all
three possible conformations, globular, ribbon, and beads (Wu
et al., 2014). This suggests the presence of factors that aid the
formation of ribbon isomers in the periplasm of E. coli in contrast
to the venom gland of the cone snail, in which the globular isomer
is formed. In that case, misfolding could be a general problem
for E. coli expression of α-conotoxins. Alternatively, TxIA could
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have features in its amino acid sequence that favor formation of
the ribbon fold, such as non-covalent interactions that stabilize
the respective cysteine positioning. For example, a study by
Kang et al. (2005) found that C-terminal amidation can cause
a preferential (but not absolute) formation of the globular form
of the 4/3-α-conotoxin ImI, supposedly by different hydrogen
bonding interactions of the C-terminus. In this context, the
potential effect of a Pro-Pro motif present in the first loop
of TxIA instead of the more common Pro-Ala motif might
also be important due to the structural constraints induced
by proline residues. However, TxIB, which appeared to fold
preferentially in the globular fold (Yu et al., 2018) has a first
loop with amino acid sequence identical to [R5D]TxIA, which
favored the ribbon conformation in our study. Thus, factors in
loop 2 of 4/7 α-conotoxins would be more likely to affect the
disulfide formation.
The inability to create post-translational modifications of
α-conotoxins in E. coli (besides disulfide bonds) is potentially
a problem as some of these modifications are important for
activity in some conotoxins. Nevertheless, certain modifications
such as tyrosine sulfation, glutamate carboxylation or C-terminal
amidation had relatively minor effects in previous studies and
might be dispensable for some toxins (Nicke et al., 2003;
Loughnan et al., 2004). In vitro modifications such as C-terminal
amidation, might also be feasible on purified recombinantly
expressed toxins (Ul-Hasan et al., 2013; Zielinski et al., 2016).
Structural Comparison of 4/7
α-Conotoxin Ribbon and Globular
Isomers
The solution structures of four ribbon α-conotoxins have been
determined and are publicly available; these include the 3/5
α-conotoxin GI (PDB 1XGB) (Gehrmann et al., 1998), the
4/4 α-conotoxin BuIA (PDB 2NS3) (Jin et al., 2007), the 4/6
α-conotoxin AuIB (PDB 1MXP) (Dutton et al., 2002), and the
4/6 α-conotoxin Pu1.2 (Carstens et al., 2016). The structures
of ribbon conotoxins are typically less well-defined than that
of the corresponding globular isomers, with Loop 1 being
relatively rigid whereas Loop 2 adopts multiple conformations,
presumably indicating a greater flexibility (Figure 6). The four
ribbon conotoxins with four residues in Loop 1, i.e., BuIA,
rAuIB, Pu1.2, and TxIA, have a very similar conformation of
Loop 1. Their Loop 2 conformations are different, reflecting the
larger structural variability of Loop 2 in globular conotoxins
(Akondi et al., 2014).
The ribbon isomers of α-conotoxins have naturally occurring
structural analogs, the cysteine Framework X, with which they
share two disulfide bridges in a ribbon isomer connectivity, a
similar size, and four cysteine residues in similar pattern along the
amino acid sequence (i.e., CC-C-C) (McIntosh et al., 2000). Loop
2 of cysteine framework X conotoxins contains only two amino
acids, with the second residue of this loop being a hydroxyproline.
The Loop 1 of framework X toxins has four residues, similar to
the cysteine Framework I α-conotoxins, but it does not contain
the Pro residue that is conserved in the α-conotoxins, and which
occupies the orthosteric binding site of nAChRs as suggested
by the crystal structures of complexes between α-conotoxins
and AChBP (Lin et al., 2016). Framework X conotoxins
are not active at nAChRs but rather target the neuronal
noradrenaline transporter, and hence they are classified in the
χ pharmacological family (Sharpe et al., 2001). Interestingly, the
ribbon isomer of an α-conotoxin was even identified in a cone
snail venom, indicating that for some α-conotoxins the ribbon
isomer is also native (Safavi-Hemami et al., 2012).
Comparison of Proposed Binding Mode
of Ribbon and Globular α-Conotoxins
A binding mode was recently proposed for the ribbon
α-conotoxin AuIB at the α3β4 nAChR (Wu et al., 2018), and
this binding mode is similar to the MD-refined binding mode
of ribbon TxIA, as illustrated in Figure 7. It was demonstrated
that the sole binding site of ribbon AuIB is at the α3(+)α3(−)
interface based on its subunit stoichiometry-dependent activity
at α3β4 nAChR (Grishin et al., 2010). Ribbon AuIB was recently
suggested to adopt a similar binding mode to that of the globular
α-conotoxin on the basis of an Ala scan which revealed that
FIGURE 6 | Comparison of the NMR solution structure of ribbon TxIA with (A) globular TxIA and (B) other ribbon contoxin structures. The first model from the NMR
ensemble was used in this figure, with the caveat that the 20 models of ribbon AuIB display a high conformational variability of Loop 2. The peptides are shown in
cartoon representations and the disulfide bonds are indicated as yellow sticks. The N- and C-termini are indicated in (A), and the hemi-cystine residues are
numbered using Roman numerals. The PDB identifier of the experimentally determined three-dimensional structures is indicated where available.
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FIGURE 7 | Comparison of the binding mode of ribbon TxIA (A) and ribbon
AuIB (B) at the interface between two α7 or α3 subunits, respectively. The
toxins are in orange, with their backbone in cartoon representation and their
side chains in stick representation. The binding site principal (+) and
complementary (–) subunits are shown in blue and wheat color, respectively.
The vicinal disulfide bond of the C-loop is shown in stick representation. The
two binding sites have been oriented similarly for convenient comparison. The
sequence of the two toxins is shown at the bottom of the figure.
most of the residues that are important for the activity of the
globular isomer are also important for the ribbon isomer (Wu
et al., 2018). Crystal structures of α-conotoxin/AChBP complexes
showed that the first loops of the globular α-conotoxins overlap
well, whereas the second loops adopt different conformations
and interactions (Dutertre et al., 2007). Like the structures
of globular α-conotoxins belonging to different loop-length
subgroups bound to the AChBPs, the conformations of the Loop
1 of ribbon 4/7 TxIA and 4/6 AuIB overlay well in the binding
sites but their second loop adopts different conformations. We
have previously been able to explain the impact of more than
30 mutants of the complex between globular α-conotoxin ImI
and the rat α7 nAChR, suggesting that our method can generate
a reasonably accurate model of the receptor (Yu et al., 2011;
Yu et al., 2012). The differences of binding modes observed
after the two refinement methods seem therefore to originate
from modeling the flexibility and interaction of the peptide.
Interestingly, ribbon [P7A]AuIB has a structure similar to
globular AuIB, but despite this change of conformation this
mutation is innocuous (Wu et al., 2018), suggesting that ribbon
AuIB would adopt a helical conformation by conformational
selection. Similarly, ribbon TxIA also becomes more helical in
both the MD- and ToxDock-refined models, suggesting that a
helical conformation is optimal for interaction. The orientations
of the loop 2 of ribbon TxIA and AuIB are different in the
binding site, although position 9 (I9 of ribbon TxIA and Y9 of
ribbon AuIB) was suggested to be buried at the interface with the
complementary subunit for both peptides. Position 9 has been
identified as a key determinant that modulates the activity of
ribbon AuIB and it could also be involved in modulation of the
activity of ribbon TxIA.
Because of their exceptional selectivity for certain ion channel
or receptor subtypes, many conopeptides are used as tools
in neuroscience and pharmacological research. Some of them
have even been developed for clinical applications such as
ω-conotoxin MVIIA (ziconitide), which is an FDA-approved
analgesic for the treatment of intractable pain (Livett et al.,
2004; Essack et al., 2012). In the case of α-conotoxins, the 4/7
α-conotoxins Vc1.1 and MII, the 4/3 α-conotoxin RgIA, and
the 4/6 α-conotoxin AuIB, were found to have potent analgesic
properties. Although there still exists some controversy regarding
their physiological target (for a recent review see, Dutertre
et al., 2017) these conotoxins are important lead structures.
New methods for large-scale production of these conotoxins and
development of a deeper understanding of their structure-activity
relationships will accelerate their development into optimized
tools and, hopefully, novel drugs.
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FIGURE S1 | Expression (A), purification (B), and analysis of antagonistic potency
(C) at α3β2 nAChR of the [R5N,I9H]TxIA double mutant.
FIGURE S2 | Second step HILIC fractionation of purified expressed TxIA analogs
and synthetic globular and ribbon TxIA isomers. Fractions containing the correct
molecular mass are highlighted in color. The red colored fractions were generally
used for all further experiments, orange colored fractions contained additional salt
ions. The dashed line indicates the gradient of solvent B (90% ACN/0.043% TFA).
MALDI MS traces indicate the monoisotopic molecular masses of the synthesized
toxins. All reported masses are for [M + H]+ ions. Note that the synthetic globular
TxIA was C-terminally amidated, explaining the difference in molecular mass to the
synthetic ribbon and recombinant TxIA (Figure 2C).
FIGURE S3 | Characterization of chemically synthesized ribbon TxIA. (A) UV
absorbance chromatogram at 214 nm of synthetic TxIA ribbon. The minor peak is
probably due to conformational exchange since the merging of the two peaks is
observed at 55◦C. ACN gradient from 0 to 100% in 2.5 min. (B) ESI-MS of
synthethic TxIA ribbon. (C) Overlay of the amide region of the TOCSY spectra for
Frontiers in Pharmacology | www.frontiersin.org 14 May 2019 | Volume 10 | Article 577
fphar-10-00577 May 29, 2019 Time: 19:41 # 15
El Hamdaoui et al. Expressed TxIA Analogs
recombinantly expressed TxIA (red) and synthetic ribbon TxIA (blue). Small
differences in chemical shift for the HN protons are observed for Cys3 and
Cys16 between samples presumably due to a slight variation in pH
between samples.
FIGURE S4 | Comparison of the interactions between the position 5 of ribbon
TxIA (A) and R5N (B) and R5D (C) variants at the α7 nAChR in the
ToxDock-refined molecular models. The α7 nAChR is in blue and the toxins in
orange. Hydrogen bonds are represented using dashed lines.
DATA SHEET S1 | Atomic coordinates files in PDB format of the molecular
models of the interaction between ribbon TxIA and the α7 nAChR. Two models are
provided, one refined using a molecular dynamics simulation and the other refined
using the ToxDock protocol.
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